Research objective: to study and analyze clinical and epidemiological features of meningococcal disease at present stage. Material and methods. A prospective analysis of the epidemiological, clinical and laboratory data was carried out in 118 patients with invasive meningococcal disease, who were hospitalized in the City Clinical Hospital of Infectious Diseases No.1 in Tashkent. Results and discussion. The epidemiological situation of meningococcal disease in Uzbekistan is characterized by signs of the inter-epidemic period, when there is an increasing incidence of meningococcal disease in the age structure, and high proportion of patients aged 7-14 years (17.9%) and 20-29 (39.8%). The leading serogroup among the laboratory-confirmed cases is the N.meningitidis serogroup A (99.1%), while currently there have been cases of disease caused by N.meningitidis serogroup W135 and C. The characteristic hemorrhagic rash associated with persistent hyperthermia which appeared only on the 3-4th day of the disease was a clinical feature of the generalized forms of meningococcal disease, which greatly complicated timely diagnosis. In patients who suffered from the combined form of meningococcal disease and "pure" meningitis we often observed such pathological complications as sensorineural hearing loss (3.3%), encephalopathy (11.8%), as well as the development of severe necrosis with scarring at the localization of rash. Conclusion. The current epidemic situation and the clinical course of invasive forms of meningococcal disease require decisive preventive measures. Nowadays, the vaccination against meningococcal infection is one of the most important trends in reducing morbidity and mortality of meningococcal disease in children and adults.
1. Koroleva I.S., Beloshitskiy G.V., Koroleva M.A. Meningococcal disease and bacterial purulent meningitis in the Russian Federation: a ten-year epidemiological observation. Epidemics and infectious diseases // Actual Issues 2013; (2): 15-20. 2. Skripchenko N.V., Vilnits A.A. Meningococcal disease in children. St. Petersburg: Tactic-Studio, 2015; 840. 3. Hong E. et al. Clonal homogenization and reproduction among invasive meningococcal serogroup III isolates in France // J. Infec. 2018; 76 (2): 149-158. 4. Ali A., Rabab Z.J., Messonnier N. et al. Global practices of meningococcal vaccine use and impact on invasive disease // Pathog Glob Health 2014; 108(1): 11–20. 5. Australian Meningococcal Surveillance Programme. Annual report, 2015. 6. Borrov R. et al. Meningococcal disease in the Asia-Pacific region: Findings and recommendations from the Global Meningococcal Initiative // Rev. Vaccine 2017; 16 (4): 313-328. 7. Borrow R et al. Meningococcal disease in the Asia-Pacific region: Findings and recommendations from the Global Meningococcal Initiative // Vaccine 2016; 34(48): 5855-5862. 8. Centers for Disease Control and Prevention (CDC). Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network Neisseria meningitidis, 2016. 9. Fukusumi M et al. National surveillance for meningococcal disease in Japan, 1999-2014.Vaccine 2016; 34(34): 4068-71. 10. Knol M.J. et all. Temporal associations between national outbreaks of meningococcal serogroup W and C disease in the Netherlands and England: an observational cohort study. Lancet Public Health 2017; (10): 473-482. 11. Lahra M.M., Enriquez R.P. National Neisseria Network, Australian Meningococcal Surveillance Programme annual report, 2015. Commun Dis Intell Q Rep. 2016; 40(4): 503-511. 12. Li Y.A., Tssang R., Desai S. et al. Enhanced surveillance of invasive meningococcal disease in Canada 2006–2011 // Canada Communicable Disease Report. Vol. 2014: 40(9): 160-169. 13. Sáfadi MA et al. Frequent capsule switching in 'ultra-virulent' meningococci - Are we ready for a serogroup B ST-11 complex outbreak. Vaccine. 2015; 33(48): 6529-36. 14. WHO, «Bacterial Meningitis», New and Under-utilized Vaccines Implementation (NUVI), 2010, http://www.who.int/nuvi/meningitis/en/index.html. 15. Jay Lucidarme, Ayswarya Lekshmi., Sydel R. et al. Frequent capsule switching in 'ultra-virulent' meningococci - Are we ready for a serogroup B ST-11 complex outbreak? J Infect/2017; 75(2): 95-103.
Daminov, Turgunpulat A.; Tuychiev, Laziz N.; Tadjieva, Nigora U.; and Murtazaeva, Ziyoda B.
"MENINGOCOCCAL DISEASE: CLINICAL AND EPIDEMIOLOGICAL FEATURES,"
Central Asian Journal of Medicine: Vol. 2020
, Article 3.
Available at: https://uzjournals.edu.uz/tma/vol2020/iss3/3